Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
CRANBURY, N.J. , February 03 /Businesswire/ - It marks Accutar as the first company to successfully bring oral chimeric degraders against three different targets into clinics.